<DOC>
	<DOCNO>NCT00411086</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood . Giving rituximab together GM-CSF may effective treatment follicular B-cell lymphoma . PURPOSE : This phase II trial study side effect well give rituximab together GM-CSF work treat patient newly diagnose follicular B-cell lymphoma .</brief_summary>
	<brief_title>Rituximab GM-CSF Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety efficacy rituximab sargramostim ( GM-CSF ) , term complete response 12 week , patient newly diagnose follicular B-cell lymphoma . Secondary - Determine overall response rate patient treat regimen . - Determine progression-free survival 3 year patient treat regimen . - Determine adverse event profile regimen patient . - Determine survival patient treat regimen . - Determine effect Fc gamma receptor polymorphism response rate time progression patient treat regimen . OUTLINE : This open-label , multicenter study . Patients receive rituximab IV day 1 , 8 , 15 , 22 sargramostim ( GM-CSF ) subcutaneously day 1 , 3 , 5 . Treatment GM-CSF repeat weekly 8 week absence disease progression unacceptable toxicity . Patients undergo blood collection baseline correlative laboratory study Fc-gamma receptor RIIIa 158 polymorphism . After completion study treatment , patient follow every 3 month 2 year every 6 month 1 year . PROJECTED ACCRUAL : A total 52 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Patients must histologically confirm newly diagnose follicular Bcell lymphoma . 2 . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; /= 20 mm conventional technique &gt; /= 10 mm spiral CT scan . 3 . Patients receive prior therapy kind follicular Bcell lymphoma . 4 . Age &gt; /= 18 year . Because dose adverse event data currently available use rituximab combination sargramostim patient ( male female ) &lt; 18 year age , child exclude study . 5 . Eastern Cooperative Oncology ( ECOG ) performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % ) . 6 . Patients must normal organ marrow function define : leukocyte &gt; /= 3,000/microL ; absolute neutrophil count &gt; /= 1,500/microL ; platelet &gt; /= 100,000/microL ; total bilirubin within normal institutional limit ; AST ( SGOT ) /ALT ( SGPT ) &lt; /= 2.5 X institutional upper limit normal ; creatinine within normal institutional limit OR creatinine clearance &gt; /= 60 mL/min/1.73 m^2 patient creatinine level institutional normal 7 . Hemoglobin &gt; /= 8.0 gm/dL 8 . The effect rituximab sargramostim develop human fetus recommend therapeutic dos unknown . For reason woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 9 . Ability understand willingness sign inform consent document . 1 . Prior therapy kind follicular Bcell lymphoma . 2 . Patients may receive investigational agent . 3 . Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . 4 . History allergic reaction attribute compound similar chemical biologic composition rituximab agent use study . 5 . Rituximab contraindicate patient know anaphylaxis IgEmediated hypersensitivity murine protein . Sargramostim contraindicate patient excessive leukemic myeloid blast , know hypersensitivity GMCSF yeastderived component recombinant , concomitant ( within 24 hour Â± ) use chemotherapy radiotherapy . 6 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 7 . Pregnant woman exclude study . 8 . Patients immune deficiency increase risk lethal infection treat marrowsuppressive therapy . Therefore , HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction . 9 . Patients evidence active prior infection Hepatitis B exclude . ( Note : Persons vaccinate Hepatitis B positive antibody exclude ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>Granulocyte-Macrophage Colony Stimulating Factor</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
</DOC>